An Analysis of Clinical and Pathologic Features, RecurIndex Genomic Profiles, and Survival Outcomes in HER2-Low Breast Cancer

• Published in: The oncologist (Dayton, Ohio) Ohio), 2023-12, Vol.28 (12), p.e1160-e1169
• Main Authors: Hui, Tianli, Li, Sainan, Wang, Huimin, Ma, Xuejiao, Du, Furong, Gao, Wei, Yang, Shan, Sang, Meixiang, Li, Ziyi, Ding, Ran, Liu, Yueping, Geng, Cuizhi
• Format: Article
• Language: English
• Subjects: Analysis; Breast Cancer; Breast Neoplasms - pathology; Clinical pathology; Cytoskeletal Proteins; Female; Gene expression; Genomics; Health aspects; Humans; Neoplasm Recurrence, Local; Prognosis; Receptor, ErbB-2 - metabolism; Receptors, Progesterone - metabolism; Retrospective Studies; Women
• ISSN: 1083-7159; 1549-490X
• DOI: 10.1093/oncolo/oyad159

In recent years, breast cancer has become the most common cancer in the world, increasing women's health risks. Approximately 60% of breast cancers are categorized as human epidermal growth factor receptor 2 (HER2)-low tumors. Recently, antibody-drug conjugates have been found to have positive anticancer efficacy in patients with HER2-low breast cancer, but more studies are required to comprehend their clinical and molecular characteristics. In this study, we retrospectively analyzed the data of 165 early breast cancer patients with pT1-2N1M0 who had undergone the RecurIndex testing. To better understand HER2-low tumors, we investigated the RecurIndex genomic profiles, clinicopathologic features, and survival outcomes of breast cancers according to HER2 status. First, there were significantly more hormone receptor (HR)-positive tumors, luminal-type tumors, and low Ki67 levels in the HER2-low than in the HER2-zero. Second, RI-LR (P = .0294) and RI-DR (P = .001) scores for HER2-low and HER2-zero were statistically significant. Third, within HER2-negative disease, HR-positive/HER2-low tumors showed highest ESR1, NFATC2IP, PTI1, ERBB2, and OBSL1 expressions. Fourth, results of the survival analysis showed that lower expression of HER2 was associated with improved relapse-free survival for HR-positive tumors, but not for HR-negative tumors. The present study highlights the unique features of HER2-low tumors in terms of their clinical characteristics as well as their gene expression profiles. HR status may influence the prognosis of patients with HER2-low expression, and patients with HR-positive/HER2-low expression may have a favorable outcome.